Clearside Biomedical, Inc. (CLSD) News
Filter CLSD News Items
CLSD News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CLSD News Highlights
- For CLSD, its 30 day story count is now at 2.
- Over the past 8 days, the trend for CLSD's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- SCS, AX and CLS are the most mentioned tickers in articles about CLSD.
Latest CLSD News From Around the Web
Below are the latest news stories about CLEARSIDE BIOMEDICAL INC that investors may wish to consider to help them evaluate CLSD as an investment opportunity.
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD- CLS-AX is a Highly Potent Tyrosine Kinase Inhibitor Delivered Suprachoroidally Using Clearside’s SCS Microinjector® - - Randomization Completed in ODYSSEY Phase 2b Clinical Trial - - Topline Data Expected in Q3 2024 - ALPHARETTA, Ga., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that it has completed randomization |
Can Clearside Biomedical (NASDAQ:CLSD) Afford To Invest In Growth?We can readily understand why investors are attracted to unprofitable companies. For example, although... |
Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Earnings Call TranscriptClearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Earnings Call Transcript November 13, 2023 Clearside Biomedical, Inc. beats earnings expectations. Reported EPS is $-0.15, expectations were $-0.16. Operator: Greetings, and welcome to the Clearside Biomedical Third Quarter 2023 Financial Results and Corporate Update Call. At this time, all participants are in a listen-only mode and a question-and-answer […] |
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update- New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside’s Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor - - BioCryst Collaboration Provides $5 Million Upfront, the Potential for Additional $77.5 Million in Clinical, Regulatory, and Sales Based Milestone Payments, Plus Royalties - - Recruitment Completed in CLS-AX Phase 2b ODYSSEY Wet AMD Trial with Topline Data Expected in Q3 2024 - - Management to Host Webcast and Conference Call Today at 4:30 |
Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare ConferenceALPHARETTA, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Wednesday, November 15, 2023 at 8:35 a.m. ET in New York, NY. A link to the live and archived webca |
Clearside Biomedical’s Versatile Suprachoroidal Injection Platform Highlighted in Four Ophthalmic Indications in Clinical Data Presentations at AAO 2023 Annual MeetingRobust Safety Profile and Encouraging Efficacy Data Utilizing SCS Microinjector® Featured in Multiple Data PresentationsALPHARETTA, Ga., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that multiple oral and poster presentations were delivered at the Annual Meeting of the American Academy of Ophthalmology (AAO) that hig |
BioCryst and Clearside Biomedical Enter Partnership to Develop Avoralstat for Diabetic Macular Edema Using Clearside’s Proprietary SCS Microinjector®– SCS Microinjector is the first and only FDA-approved approach to access the suprachoroidal space – – BioCryst to host R&D Day today at 1:00 pm ET – ALPHARETTA, Ga. and RESEARCH TRIANGLE PARK, N.C., Nov. 03, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Clearside Biomedical, Inc. (Nasdaq: CLSD) today announced the entry into a license agreement enabling BioCryst to develop its investigational plasma kallikrein inhibitor, avoralstat, with Clearside’s SCS Microinjecto |
Clearside Biomedical Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting- Clinical Data Utilizing Clearside’s Suprachoroidal Delivery Technology to be Featured in Multiple Oral and Poster Presentations -ALPHARETTA, Ga., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that multiple oral and poster presentations will be delivered at the American Academy of Ophthalmology (AAO) 2023 Annual Meet |
Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD- Successful Completion of Recruitment Driven by Strong Clinical Site Participation and Investigator Support - - Topline Data Expected in Q3 2024 - ALPHARETTA, Ga., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the completion of recruitment in its ODYSSEY Phase 2b clinical trial, a randomized, double-masked, parallel- |
Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023ALPHARETTA, Ga., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its third quarter 2023 financial results will be reported on Monday, November 13, 2023, after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corpora |